Zacks Investment Research Upgrades Entellus Medical, Inc. (ENTL) to “Buy”

Zacks Investment Research upgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a sell rating to a buy rating in a research note published on Monday morning. The firm currently has $23.00 price target on the medical technology company’s stock.

According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “

A number of other analysts have also commented on ENTL. BidaskClub lowered shares of Entellus Medical from a buy rating to a hold rating in a report on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a buy rating and set a $21.00 target price on shares of Entellus Medical in a report on Tuesday, August 22nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of $22.00.

Shares of Entellus Medical (NASDAQ ENTL) remained flat at $19.03 during midday trading on Monday. 8,428 shares of the company’s stock traded hands. The company’s market capitalization is $482.81 million. The company’s 50 day moving average is $18.28 and its 200-day moving average is $18.28. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.69.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same period in the prior year, the firm posted ($0.27) EPS. Entellus Medical’s revenue was up 18.0% on a year-over-year basis. On average, equities analysts forecast that Entellus Medical will post ($1.61) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Entellus Medical, Inc. (ENTL) to “Buy”” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://baseballnewssource.com/markets/zacks-investment-research-upgrades-entellus-medical-inc-entl-to-buy/1704495.html.

In other news, VP Stephen R. Paidosh sold 25,000 shares of Entellus Medical stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $17.54, for a total transaction of $438,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Brian E. Farley sold 40,000 shares of Entellus Medical stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $19.78, for a total transaction of $791,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,650 shares of company stock worth $1,510,252. Insiders own 7.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Eqis Capital Management Inc. boosted its position in shares of Entellus Medical by 20.0% during the third quarter. Eqis Capital Management Inc. now owns 43,929 shares of the medical technology company’s stock worth $811,000 after purchasing an additional 7,311 shares in the last quarter. Paulson & CO. Inc. bought a new position in shares of Entellus Medical during the second quarter worth $1,701,000. Wasatch Advisors Inc. boosted its position in shares of Entellus Medical by 6.7% during the second quarter. Wasatch Advisors Inc. now owns 231,656 shares of the medical technology company’s stock worth $3,836,000 after purchasing an additional 14,462 shares in the last quarter. Grandeur Peak Global Advisors LLC boosted its position in shares of Entellus Medical by 3.5% during the second quarter. Grandeur Peak Global Advisors LLC now owns 219,971 shares of the medical technology company’s stock worth $3,643,000 after purchasing an additional 7,480 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Entellus Medical by 26.4% during the second quarter. California State Teachers Retirement System now owns 21,517 shares of the medical technology company’s stock worth $356,000 after purchasing an additional 4,500 shares in the last quarter. 70.27% of the stock is currently owned by institutional investors.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell


Leave a Reply

 
© 2006-2017 BBNS.